|
Non-muscle invasive bladder cancer (NMIBC) is a form of cancer with a high recurrence rate and limited treatment options. Currently best results are achieved when BCG (Bacillus Calmette-Guerin) is used together with photodynamic diagnosis (PDD) and TURBT (trans urethral resection of bladder tumor) but majority of NMIBC still recur after the initial treatment. Even though PDD is commonly used to visualize the lesions as part of a TURBT procedure, photosensitive drug compounds have had limited success in clinical setting partly because of limitations in light sources and light delivery optics. Modulight has extended its multi-indication laser platform to support the use of a novel photosensitive drug for NMIBC. The properties of different tumor types (papillary vs carcinoma in situ (CIS)) require different illumination methods and laser parameters and illumination modes have been defined accordingly. Laser system has been designed to support both focused illumination of localized lesions and overall illumination of the entire bladder to cover possible scattered CIS lesions. Light delivery system optimization has included compatibility testing with flexible cystoscopes and investigation of the light delivery system performance in bladder environment. Connectivity features of the laser system have been tailored to support documentation requirements in clinical trials by enabling treatment configuration and realized treatment log storage in Modulight cloud. Ongoing work and future plans include treatment monitoring and imaging capabilities integration in treatment flow with the aim to have a comprehensive laser platform that can support white light imaging, fluorescence imaging, and a variety of light-based treatment modalities |
|
|
